GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated September 21, 2022, serves as a transaction notification for the month of September 2022. The document discloses specific share awards made to Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them under the Company's 2015 Share Value Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of insider share transactions.
Material Changes and Transactions
The filing details two specific share award transactions conducted on September 5, 2022:
- Recipient 1: Mrs. V A Whyte (SVP & Company Secretary). Received an award of 10,050 Ordinary Shares at a price of £13.578 per share.
- Recipient 2: Mr. D Jackson (PCA of Ms. S Jackson, SVP, Global Communications and CEO Office). Received an award of 6,330 Ordinary Shares at a price of £13.578 per share.
Total shares awarded in this notification: 16,380 Ordinary Shares (ISIN: GB00BN7SWP63).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It is limited to the statutory reporting of the aforementioned share awards.
Key Facts for Investor Verification
- Verify the total number of shares awarded to executives and their associates during the reporting period.
- Confirm the transaction price of £13.578 per share against the market price on September 5, 2022.
- Ensure these awards align with the terms of the GSK 2015 Share Value Plan.
- Note that this filing does not reflect the company's overall financial performance for the quarter or year.